Direct Oral Anticoagulants (DOACs) are a class of blood thinners that work by directly blocking a single blood clotting factor (such as Factor Xa or thrombin) to treat or prevent blood clots, commonly used in conditions like deep vein thrombosis and thromboembolism.

Google

To understand and manage potential drug-drug interactions in COVID-19 treatments, key pharmacological, biochemical, and physiological concepts are classified into the following groups:
- **General Pharmacology**: Pharmacokinetics and pharmacodynamics.
- **Drug Transporters**: Organic Anion Transporters (OAT), Organic Anion Transporting Polypeptides (OATP), Organic Cation Transporters (OCT), and P-glycoprotein (P-gp/MDR1).
- **Intracellular Signaling Pathways**: Janus Kinases (JAK), Signal Transducers and Activators of Transcription (STAT), and Mechanistic Target of Rapamycin (mTOR).
- **Enzymatic Metabolism**: Cytochrome P450 (CYP) enzymes.
- **Cardiac Electrophysiology Risk**: QT prolongation, Torsades de Pointes, and bradycardia.

Classification of Pharmacological and Physiological Concepts in COVID-19 Therapies

Direct Oral Anticoagulants (DOACs)

P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is an active efflux membrane transporter that limits oral drug absorption and mediates the biliary and renal excretion of cationic and amphiphilic substrates.

P-glycoprotein (MDR1) Transporter

The Cytochrome P450 (CYP) superfamily is a major group of enzymes, primarily localized in the liver, that plays a critical role in the metabolic clearance and biotransformation of various drugs and endogenous compounds.

Learn Before

Related